Stephen F. Mahoney bought $499K of Viridian Therapeutics (VRDN)
Executed Sep 27 2024, disclosed Sep 30 2024, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 30 2024), the stock returned +2.3% (delay-adjusted); from the execution session (Sep 27 2024), -1.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Stephen F. Mahoney (President and CEO) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Viridian Therapeutics, Inc. (VRDN). Across 1 priced purchase filing, the average 21-session return was -1.1% from execution and +2.3% from disclosure (delay-adjusted; derived). The largest single filing was $499K of VRDN (21,400 sh × $23.33, as filed), executed Sep 27 2024.
Healthcare · Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→